Structure Therapeutics (GPCR) Other Non-Current Liabilities (2023 - 2026)
Quarterly Other Non-Current Liabilities rose 180.19% to $863000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $863000.0 through Mar 2026, up 180.19% year-over-year, with the annual reading at $647000.0 for FY2025, 114.24% up from the prior year.
Structure Therapeutics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $863000.0 for Q1 2026.
- Other Non-Current Liabilities came in at $863000.0 for Q1 2026, up from $647000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $863000.0 in Q1 2026 to a low of $281000.0 in Q3 2023.
- The 4-year median for Other Non-Current Liabilities is $309000.0 (2024), against an average of $403727.3.
- Year-over-year, Other Non-Current Liabilities tumbled 39.6% in 2024 and then soared 180.19% in 2026.
- Structure Therapeutics' Other Non-Current Liabilities stood at $500000.0 in 2023, then crashed by 39.6% to $302000.0 in 2024, then soared by 114.24% to $647000.0 in 2025, then surged by 33.38% to $863000.0 in 2026.
- Per Business Quant, the three most recent readings for GPCR's Other Non-Current Liabilities are $863000.0 (Q1 2026), $647000.0 (Q4 2025), and $325000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Structure Therapeutics | 8.43 Bn | 8.43 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 863,000.00 |
| Dec 31, 2025 | 647,000.00 |
| Sep 30, 2025 | 325,000.00 |
| Jun 30, 2025 | 317,000.00 |
| Mar 31, 2025 | 308,000.00 |
| Dec 31, 2024 | 302,000.00 |
| Sep 30, 2024 | 309,000.00 |
| Jun 30, 2024 | 293,000.00 |
| Mar 31, 2024 | 296,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 281,000.00 |